Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: A molecular target for anti-angiogenic therapy?

Current Cancer Drug Targets

Volumn 10, Issue 8, 2010, Pages 890-897

  Staufer, K ^a   Stoeltzing, O ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Cancer; Endothelial cells; Heat shock protein 90; Resistance

Indexed keywords

2 AMINO 6 CHLORO 9 [(4 METHOXY 3,5 DIMETHYL 2 PYRIDINYL)METHYL]PURINE; 3 (5 CHLORO 2,4 DIHYDROXYPHENYL) N ETHYL 4 (4 METHOXYPHENYL) 5 PYRAZOLECARBOXAMIDE; 4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; 4 [[2 CARBAMOYL 5 (4,5,6,7 TETRAHYDRO 6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 1H INDAZOL 1 YL)PHENYL]AMINO]CYCLOHEXYL GLYCINATE; ALVESPIMYCIN; ANGIOPOIETIN 1; FOCAL ADHESION KINASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; INTEGRIN LINKED KINASE; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETASPIMYCIN; TANESPIMYCIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL SURVIVAL; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR VASCULARIZATION; DRUG ANTAGONISM; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79956077516     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800910793357934     Document Type: Article

References (105)

1. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358(19), 2039-2049.
2. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6), 669-676.
3. Ferrara, N.; Heinsohn, H.; Walder, C. E.; Bunting, S.; Thomas, G. R. The regulation of blood vessel growth by vascular endothelial growth factor. Ann. N. Y. Acad. Sci. 1995, 752, 246-256.
4. Thurston, G.; Kitajewski, J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br. J. Cancer 2008, 99(8), 1204-1209.
5. Donate, F.; Parry, G. C.; Shaked, Y.; Hensley, H.; Guan, X.; Beck, I.; Tel-Tsur, Z.; Plunkett, M. L.; Manuia, M.; Shaw, D. E.; Kerbel, R. S.; Mazar, A. P. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCNNH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin. Cancer Res. 2008, 14(7), 2137-2144.
6. Ruegg, C.; Mariotti, A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol. Life Sci. 2003, 60(6), 1135-1157.
7. Thomas, M.; Augustin, H. G. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12(2), 125-137.
8. Wang, L.; Dutta, S. K.; Kojima, T.; Xu, X.; Khosravi-Far, R.; Ekker, S. C.; Mukhopadhyay, D. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PloS One 2007, 2(11), e1161.
9. Denes, L.; Jednakovits, A.; Hargitai, J.; Penzes, Z.; Balla, A.; Talosi, L.; Krajcsi, P.; Csermely, P. Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br. J. Pharmacol. 2002, 136(4), 597-603.
10. Genersch, E.; Hayess, K.; Neuenfeld, Y.; Haller, H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and-independent pathways. J. Cell Sci. 2000, 113(Pt 23), 4319-4330.
11. Lee, S. J.; Namkoong, S.; Kim, Y. M.; Kim, C. K.; Lee, H.; Ha, K. S.; Chung, H. T.; Kwon, Y. G.; Kim, Y. M. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK-and PI3K/Akt/eNOS-dependent signal pathways. Am. J. Physiol. 2006, 291(6), H2836-2846.
12. Masson-Gadais, B.; Houle, F.; Laferriere, J.; Huot, J. Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 2003, 8(1), 37-52.
13. Murphy, D. A.; Makonnen, S.; Lassoued, W.; Feldman, M. D.; Carter, C.; Lee, W. M. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol. 2006, 169(5), 1875-1885.
14. Phung, T. L.; Ziv, K.; Dabydeen, D.; Eyiah-Mensah, G.; Riveros, M.; Perruzzi, C.; Sun, J.; Monahan-Earley, R. A.; Shiojima, I.; Nagy, J. A.; Lin, M. I.; Walsh, K.; Dvorak, A. M.; Briscoe, D. M.; Neeman, M.; Sessa, W. C.; Dvorak, H. F.; Benjamin, L. E. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006, 10(2), 159-170.
15. Srinivasan, R.; Zabuawala, T.; Huang, H.; Zhang, J.; Gulati, P.; Fernandez, S.; Karlo, J. C.; Landreth, G. E.; Leone, G.; Ostrowski, M. C. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PloS One 2009, 4(12), e8283.
16. Yang, Y. H.; Wang, Y.; Lam, K. S.; Yau, M. H.; Cheng, K. K.; Zhang, J.; Zhu, W.; Wu, D.; Xu, A. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietinlike protein 4. Arterioscler. Thromb. Vasc. Biol. 2008, 28(5), 835-840.
17. Korpelainen, E. I.; Karkkainen, M.; Gunji, Y.; Vikkula, M.; Alitalo, K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999, 18(1), 1-8.
18. Milkiewicz, M.; Doyle, J. L.; Fudalewski, T.; Ispanovic, E.; Aghasi, M.; Haas, T. L. HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. J. Physiol. 2007, 583(Pt 2), 753-766.
19. Yang, X.; Qiao, D.; Meyer, K.; Friedl, A. Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res. 2009, 69(4), 1668-1677.
20. Kim, K. W.; Bae, S. K.; Lee, O. H.; Bae, M. H.; Lee, M. J.; Park, B. C. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998, 58(2), 348-351.
21. Lee, O. H.; Bae, S. K.; Bae, M. H.; Lee, Y. M.; Moon, E. J.; Cha, H. J.; Kwon, Y. G.; Kim, K. W. Identification of angiogenic properties of insulinlike growth factor II in in vitro angiogenesis models. Br. J. Cancer 2000, 82(2), 385-391.
22. Zhang, J.; Cao, R.; Zhang, Y.; Jia, T.; Cao, Y.; Wahlberg, E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2009, 23(1), 153-163.
23. Ding, S.; Merkulova-Rainon, T.; Han, Z. C.; Tobelem, G. HGF receptor upregulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101(12), 4816-4822.
24. Tomita, N.; Morishita, R.; Taniyama, Y.; Koike, H.; Aoki, M.; Shimizu, H.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003, 107(10), 1411-1417.
25. Barginear, M. F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C. A.; Budman, D. R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8(6), 522-532.
26. Chiosis, G. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer. Expert Opin. Ther. Targets 2006, 10(1), 37-50.
27. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5(10), 761-772.
28. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol. Life Sci. 2002, 59(10), 1640-1648.
29. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, F. U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 2004, 5(10), 781-791.
30. Neckers, L. Heat shock protein 90: the cancer chaperone. J. Biosci. 2007, 32(3), 517-530.
31. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82(8), 488-499.
32. Gabai, V. L.; Mosina, V. A.; Budagova, K. R.; Kabakov, A. E. Spontaneous overexpression of heat-shock proteins in Ehrlich ascites carcinoma cells during in vivo growth. Biochem. Mol. Biol. Int. 1995, 35(1), 95-102.
33. Lebeau, J.; Le Chalony, C.; Prosperi, M. T.; Goubin, G. Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harveyras oncogene. Oncogene 1991, 6(7), 1125-1132.
34. Gooljarsingh, L. T.; Fernandes, C.; Yan, K.; Zhang, H.; Grooms, M.; Johanson, K.; Sinnamon, R. H.; Kirkpatrick, R. B.; Kerrigan, J.; Lewis, T.; Arnone, M.; King, A. J.; Lai, Z.; Copeland, R. A.; Tummino, P. J. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. USA 2006, 103(20), 7625-7630.
35. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425(6956), 407-410.
36. de Candia, P.; Solit, D. B.; Giri, D.; Brogi, E.; Siegel, P. M.; Olshen, A. B.; Muller, W. J.; Rosen, N.; Benezra, R. Angiogenesis impairment in Iddeficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc. Natl. Acad. Sci. USA 2003, 100(21), 12337-12342.
37. Isaacs, J. S.; Xu, W.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3(3), 213-217.
38. Xue, Q.; Nagy, J. A.; Manseau, E. J.; Phung, T. L.; Dvorak, H. F.; Benjamin, L. E. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler. Thromb. Vasc. Biol. 2009, 29(8), 1172-1178.
39. Antonova, G.; Lichtenbeld, H.; Xia, T.; Chatterjee, A.; Dimitropoulou, C.; Catravas, J. D. Functional significance of hsp90 complexes with NOS and sGC in endothelial cells. Clin. Hemorheol. Microcirc. 2007, 37(1-2), 19-35.
40. Takahashi, S.; Mendelsohn, M. E. Synergistic activation of endothelial nitricoxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J. Biol. Chem. 2003, 278(33), 30821-30827.
41. Kaur, G.; Belotti, D.; Burger, A. M.; Fisher-Nielson, K.; Borsotti, P.; Riccardi, E.; Thillainathan, J.; Hollingshead, M.; Sausville, E. A.; Giavazzi, R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 2004, 10(14), 4813-4821.
42. Lang, S. A.; Moser, C.; Fichnter-Feigl, S.; Schachtschneider, P.; Hellerbrand, C.; Schmitz, V.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Targeting heatshock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology (Baltimore, MD) 2009, 49(2), 523-532.
43. Sanderson, S.; Valenti, M.; Gowan, S.; Patterson, L.; Ahmad, Z.; Workman, P.; Eccles, S. A. Benzoquinone ansamycin heat shock protein 90 inhibitorsmodulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 2006, 5(3), 522-532.
44. Fukumura, D.; Gohongi, T.; Kadambi, A.; Izumi, Y.; Ang, J.; Yun, C. O.; Buerk, D. G.; Huang, P. L.; Jain, R. K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA 2001, 98(5), 2604-2609.
45. Sun, J.; Liao, J. K. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler. Thromb. Vasc. Biol. 2004, 24(12), 2238-2244.
46. Miao, R. Q.; Fontana, J.; Fulton, D.; Lin, M. I.; Harrison, K. D.; Sessa, W. C. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28(1), 105-111.
47. Chen, J. X.; Lawrence, M. L.; Cunningham, G.; Christman, B. W.; Meyrick, B. HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium. J. Appl. Physiol. 2004, 96(2), 612-620.
48. Duval, M.; Le Boeuf, F.; Huot, J.; Gratton, J. P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell. 2007, 18(11), 4659-4668.
49. Brouet, A.; Sonveaux, P.; Dessy, C.; Moniotte, S.; Balligand, J. L.; Feron, O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxidemediated effects of statins. Circ. Res. 2001, 89(10), 866-873.
50. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20(21), 4368-4380.
51. Kawamura, H.; Li, X.; Goishi, K.; van Meeteren, L. A.; Jakobsson, L.; Cebe-Suarez, S.; Shimizu, A.; Edholm, D.; Ballmer-Hofer, K.; Kjellen, L.; Klagsbrun, M.; Claesson-Welsh, L. Neuropilin-1 in regulation of VEGFinduced activation of p38MAPK and endothelial cell organization. Blood 2008, 112(9), 3638-3649.
52. Miao, H. Q.; Klagsbrun, M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev. 2000, 19(1-2), 29-37.
53. Parikh, A. A.; Fan, F.; Liu, W. B.; Ahmad, S. A.; Stoeltzing, O.; Reinmuth, N.; Bielenberg, D.; Bucana, C. D.; Klagsbrun, M.; Ellis, L. M. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am. J. Pathol. 2004, 164(6), 2139-2151.
54. Stuttfeld, E.; Ballmer-Hofer, K. Structure and function of VEGF receptors. IUBMB Life 2009, 61(9), 915-922.
55. Okawa, Y.; Hideshima, T.; Steed, P.; Vallet, S.; Hall, S.; Huang, K.; Rice, J.; Barabasz, A.; Foley, B.; Ikeda, H.; Raje, N.; Kiziltepe, T.; Yasui, H.; Enatsu, S.; Anderson, K. C. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113(4), 846-855.
56. Rice, J. W.; Veal, J. M.; Fadden, R. P.; Barabasz, A. F.; Partridge, J. M.; Barta, T. E.; Dubois, L. G.; Huang, K. H.; Mabbett, S. R.; Silinski, M. A.; Steed, P. M.; Hall, S. E. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58(12), 3765-3775.
57. Sharp, S. Y.; Prodromou, C.; Boxall, K.; Powers, M. V.; Holmes, J. L.; Box, G.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; James, K.; Hayes, A.; Hardcastle, A.; Dymock, B.; Brough, P. A.; Barril, X.; Cansfield, J. E.; Wright, L.; Surgenor, A.; Foloppe, N.; Hubbard, R. E.; Aherne, W.; Pearl, L.; Jones, K.; McDonald, E.; Raynaud, F.; Eccles, S.; Drysdale, M.; Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 2007, 6(4), 1198-1211.
58. Park, J. H.; Kim, S. H.; Choi, M. C.; Lee, J.; Oh, D. Y.; Im, S. A.; Bang, Y. J.; Kim, T. Y. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 2008, 368(2), 318-322.
59. Soker, S.; Takashima, S.; Miao, H. Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92(6), 735-745.
60. Brindle, N. P.; Saharinen, P.; Alitalo, K. Signaling and functions of angiopoietin-1 in vascular protection. Circ. Res. 2006, 98(8), 1014-1023.
61. Giuliani, N.; Colla, S.; Morandi, F.; Rizzoli, V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk. Lymphoma 2005, 46(1), 29-33.
62. Tramentozzi, E.; Montopoli, M.; Orso, G.; Pagetta, A.; Caparrotta, L.; Frasson, M.; Brunati, A. M.; Finotti, P. Stable complexes formed by Grp94 with human IgG promoting angiogenic differentiation of HUVECs by a cytokinelike mechanism. Mol. Immunol. 2008, 45(13), 3639-3648.
63. Wang, Y. Q.; Zhang, X. M.; Wang, X. D.; Wang, B. J.; Wang, W. 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1alpha and ILK in mouse RPE cells. Mol. Biol. Rep. 2010, 37(3), 1203-1209.
64. Koshida, R.; Ou, J.; Matsunaga, T.; Chilian, W. M.; Oldham, K. T.; Ackerman, A. W.; Pritchard, K. A., Jr. Angiostatin: a negative regulator of endothelial-dependent vasodilation. Circulation 2003, 107(6), 803-806.
65. Schwartz, J.; Pinilla-Ibarz, J.; Yuan, R. R.; Scheinberg, D. A. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin. Hematol. 2003, 40(1), 87-96.
66. Sharp, S. Y.; Boxall, K.; Rowlands, M.; Prodromou, C.; Roe, S. M.; Maloney, A.; Powers, M.; Clarke, P. A.; Box, G.; Sanderson, S.; Patterson, L.; Matthews, T. P.; Cheung, K. M.; Ball, K.; Hayes, A.; Raynaud, F.; Marais, R.; Pearl, L.; Eccles, S.; Aherne, W.; McDonald, E.; Workman, P. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 2007, 67(5), 2206-2216.
67. Turkson, J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets. 2004, 8(5), 409-422.
68. Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 2003, 54, 17-28.
69. Harris, A. L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2(1), 38-47.
70. Hu, R.; Dai, A.; Tan, S. Hypoxia-inducible factor 1 alpha upregulates the expression of inducible nitric oxide synthase gene in pulmonary arteries of hyposic rat. Chin. Med. J. (Engl.) 2002, 115(12), 1833-1837.
71. Simon, M. C.; Ramirez-Bergeron, D.; Mack, F.; Hu, C. J.; Pan, Y.; Mansfield, K. Hypoxia, HIFs, and cardiovascular development. Cold Spring Harb. Symp. Quant. Biol. 2002, 67, 127-132.
72. Ema, M.; Taya, S.; Yokotani, N.; Sogawa, K.; Matsuda, Y.; Fujii-Kuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxiainducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 1997, 94(9), 4273-4278.
73. Minet, E.; Mottet, D.; Michel, G.; Roland, I.; Raes, M.; Remacle, J.; Michiels, C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999, 460(2), 251-256.
74. Osada, M.; Imaoka, S.; Funae, Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett. 2004, 575(1-3), 59-63.
75. Niu, G.; Wright, K. L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L. M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13), 2000-2008.
76. Chen, S. H.; Murphy, D. A.; Lassoued, W.; Thurston, G.; Feldman, M. D.; Lee, W. M. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol. Ther. 2008, 7(12), 1994-2003.
77. Cheranov, S. Y.; Karpurapu, M.; Wang, D.; Zhang, B.; Venema, R. C.; Rao, G. N. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 2008, 111(12), 5581-5591.
78. Lang, S. A.; Brecht, I.; Moser, C.; Obed, A.; Batt, D.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. Langenbecks Arch. Surg. 2008, 393(3), 333-341.
79. Hilfiker-Kleiner, D.; Limbourg, A.; Drexler, H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc. Med. 2005, 15(4), 152-157.
80. Bartoli, M.; Platt, D.; Lemtalsi, T.; Gu, X.; Brooks, S. E.; Marrero, M. B.; Caldwell, R. B. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003, 17(11), 1562-1564.
81. Koga, F.; Tsutsumi, S.; Neckers, L. M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle (Georgetown, TX) 2007, 6(11), 1393-1402.
82. Lang, S. A.; Klein, D.; Moser, C.; Gaumann, A.; Glockzin, G.; Dahlke, M. H.; Dietmaier, W.; Bolder, U.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol. Cancer Ther. 2007, 6(3), 1123-1132.
83. Han, J. Y.; Oh, S. H.; Morgillo, F.; Myers, J. N.; Kim, E.; Hong, W. K.; Lee, H. Y. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl. Cancer Inst. 2005, 97(17), 1272-1286.
84. Kurebayashi, J.; Otsuki, T.; Kurosumi, M.; Soga, S.; Akinaga, S.; Sonoo, H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J. Cancer Res. 2001, 92(12), 1342-1351.
85. Nagengast, W. B.; de Korte, M. A.; Oude Munnink, T. H.; Timmer-Bosscha, H.; den Dunnen, W. F.; Hollema, H.; de Jong, J. R.; Jensen, M. R.; Quadt, C.; Garcia-Echeverria, C.; van Dongen, G. A.; Lub-de Hooge, M. N.; Schroder, C. P.; de Vries, E. G. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J. Nucl. Med. 2010, 51(5), 761-767.
86. Chung, S. W.; Lee, J. H.; Choi, K. H.; Park, Y. C.; Eo, S. K.; Rhim, B. Y.; Kim, K. Extracellular heat shock protein 90 induces interleukin-8 in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2009, 378(3), 444-449.
87. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68(8), 2850-2860.
88. Lang, S. A.; Moser, C.; Gaumann, A.; Klein, D.; Glockzin, G.; Popp, F. C.; Dahlke, M. H.; Piso, P.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res. 2007, 13(21), 6459-6468.
89. Rini, B. I.; Atkins, M. B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10(10), 992-1000.
90. Blagosklonny, M. V. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol. Ther. 2005, 4(12), 1307-1310.
91. Schultheis, A. M.; Lurje, G.; Rhodes, K. E.; Zhang, W.; Yang, D.; Garcia, A. A.; Morgan, R.; Gandara, D.; Scudder, S.; Oza, A.; Hirte, H.; Fleming, G.; Roman, L.; Lenz, H. J. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 2008, 14(22), 7554-7563.
92. Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010, 21(1), 21-26.
93. Bohonowych, J. E.; Gopal, U.; Isaacs, J. S. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J. Oncol. 2010, 412985.
94. Alqawi, O.; Moghaddas, M.; Singh, G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prost. Dis. 2006, 9(2), 126-135.
95. Solit, D. B.; Zheng, F. F.; Drobnjak, M.; Munster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8(5), 986-993.
96. Kim, W. Y.; Oh, S. H.; Woo, J. K.; Hong, W. K.; Lee, H. Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009, 69(4), 1624-1632.
97. Moser, C.; Lang, S. A.; Kainz, S.; Gaumann, A.; Fichtner-Feigl, S.; Koehl, G. E.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol. Cancer Ther. 2007, 6(11), 2868-2878.
98. Song, D.; Chaerkady, R.; Tan, A. C.; Garcia-Garcia, E.; Nalli, A.; Suarez-Gauthier, A.; Lopez-Rios, F.; Zhang, X. F.; Solomon, A.; Tong, J.; Read, M.; Fritz, C.; Jimeno, A.; Pandey, A.; Hidalgo, M. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 2008, 7(10), 3275-3284.
99. Leow, C. C.; Chesebrough, J.; Coffman, K. T.; Fazenbaker, C. A.; Gooya, J.; Weng, D.; Coats, S.; Jackson, D.; Jallal, B.; Chang, Y. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther. 2009, 8(8), 2131-2141.
100. Boll, B.; Eltaib, F.; Reiners, K. S.; von Tresckow, B.; Tawadros, S.; Simhadri, V. R.; Burrows, F. J.; Lundgren, K.; Hansen, H. P.; Engert, A.; von Strandmann, E. P. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin. Cancer Res. 2009, 15(16), 5108-5116.
101. Yin, X.; Zhang, H.; Lundgren, K.; Wilson, L.; Burrows, F.; Shores, C. G. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int. J. Cancer 2010, 126(5), 1216-1225.
102. Zhang, H.; Neely, L.; Lundgren, K.; Yang, Y. C.; Lough, R.; Timple, N.; Burrows, F. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer 2010, 126(5), 1226-1234.
103. Cerchietti, L. C.; Lopes, E. C.; Yang, S. N.; Hatzi, K.; Bunting, K. L.; Tsikitas, L. A.; Mallik, A.; Robles, A. I.; Walling, J.; Varticovski, L.; Shaknovich, R.; Bhalla, K. N.; Chiosis, G.; Melnick, A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 2009, 15(12), 1369-1376.
104. Breinig, M.; Caldas-Lopes, E.; Goeppert, B.; Malz, M.; Rieker, R.; Bergmann, F.; Schirmacher, P.; Mayer, M.; Chiosis, G.; Kern, M. A. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology (Baltimore, MD) 2009, 50(1), 102-112.
105. Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; Norton, L.; Rosen, N.; Solit, D. B. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 2008, 14(1), 240-248.